XERS Xeris Biopharma Holdings, Inc. Insider Trading

CFO Kevin McCulloch bought 25,000 XERS shares at $4.38; stock -25.0% from 52-week high, company posting losses.

Kevin McCulloch purchased 25,000 shares at $4.38 on 2025-06-13, increasing his holdings from 1,683,585 shares to 1,708,585 shares (a 1.5% increase). The transaction occurs against a backdrop of significant price pressure: the stock has declined 9.8% over the last 30 days, 15.7% over 90 days, and is now 25.0% below its 52-week high of $5.87. Despite positive revenue growth of 23.9% year-over-year and recent quarterly revenue of $60.1M, the company remains unprofitable with a full-year net loss and most recent quarterly loss of $9.2M. This purchase by a senior executive adds to his substantial existing position but occurs when the stock is materially off recent highs and the company is not yet cash-flow positive.

Director John P. Schmid bought 4,515 shares of XERS at $2.25 on 2024-08-12; post-buy holding 25,200 shares (+21.8%).

Director John P. Schmid purchased 4,515 shares of Xeris Biopharma at $2.25 on 2024-08-12, increasing his holdings to 25,200 shares, a 21.8% increase from his prior 20,685-share position. This transaction follows a buy placed just three days prior (2024-08-09), suggesting sustained accumulation during a period when the stock has appreciated 28.3% over 90 days and is trading 7.9% higher over the past 30 days. Notably, Schmid's three prior measurable purchases at XERS yielded positive 90-day returns (16.8%, 3.7%, and 112.6%), establishing a pattern of well-timed entry points at this ticker. The company remains unprofitable with a net loss of $15,005,000.00 against revenue of $48,065,000.00, though it has grown revenue 48.7% year-over-year, so this purchase occurs while the stock is discounted 21.1% from its 52-week high despite recent momentum.

Director Schmid buys 4,285 XERS shares at $2.36; increases stake 26.1%, mirrors strong timing pattern in prior same-ticker buys

John P. Schmid, a director, purchased 4,285 shares of Xeris Biopharma at $2.36 on 2024-08-09, increasing his holdings by 26.1% to 20,685 shares. This transaction is notable because Schmid's prior three measurable purchases at Xeris—on 2024-05-10, 2024-03-14, and 2023-11-16—all posted positive 90-day returns of +16.8%, +3.7%, and +112.6% respectively, demonstrating a consistent pattern of well-timed entry points at this specific ticker. However, the company remains unprofitable with a net loss of $15,005,000.00 against latest-quarter revenue of $48,065,000.00, and the stock has declined 30.1% from its 52-week high of $3.22 to the current $2.25. The repeat purchase at a depressed valuation within this unprofitable company occurs against Schmid's cross-ticker track record showing 60.00% win rate on buys over 90 days, which provides some supporting context but does not override the fundamental weakness of the underlying business.